Intellia Therapeutics Investor Presentation — February 2018

Document content

Building a Full -spectrum Genome Editing Company

Intellia Therapeutics Legal Disclaimers

This presentation contains “forward -looking statements” ofIntellia

Therapeutics, Inc.within themeaning ofthePrivate Securities Litigation

Reform Actof1995 .These forward -looking statements include, butare

notlimited to,express orimplied statements regarding Intellia’s ability to

advance and expand theCRISPR/Cas 9technology todevelop into

human therapeutic products, aswell asourCRISPR/Cas 9intellectual

property portfolio ;ourability toachieve stable oreffective genome

editing ;ourability toadminister multiple doses ofourCRISPR/Cas 9

product candidates ;the potential timing and advancement ofour

preclinical studies, including continuing non-human primate studies for

ourATTR program andother programs, andclinical trials;thetiming and

potential achievement ofmilestones toadvance ourpipeline ;ourability to

replicate results achieved inourpreclinical studies inanyfuture studies,

including human clinical trials;thepotential development ofexvivo cell

therapeutics ofalltypes, and those targeting WT1inparticular, using

CRISPR/Cas 9technology ;ourability tocontinue toconduct successful

IND-enabling studies ofalead ATTR development candidate and

subsequently submitting anINDapplication bytheendof2019 thatwill

beaccepted bytheregulatory agencies ;ourintent topresent additional

data fororgans beyond theliver, additional insertion/repair data, and

preclinical data insupport ofourfirst exvivo programs onimmuno -

oncology and autoimmune/inflammation indications during 2018 ;the

expansion ofourfully automated bioinformatics platform ;ourability to

advance adevelopment candidate forasecond indication bylate2018 ;

ourpotential ability toconduct apre-INDmeeting withtheFDA forATTR ;

theintellectual property position and strategy ofIntellia’s licensors or

other parties from which itderives rights ;actions bygovernment

agencies ;theimpact ofourcollaborations onourdevelopment programs ;

Preview truncated — download the full document for the complete content.